Local therapies for hepatic metastases

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 2, 2013, Pages 153-160

  Johnston, Fabian M ^a   Mavros, Michael N ^a   Herman, Joseph M ^b   Pawlik, Timothy M ^a,c  

^a Departments of Surgery   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; OCTREOTIDE; OXALIPLATIN; SUNITINIB; YTTRIUM 90;

ARTERY CATHETERIZATION; ARTICLE; ARTIFICIAL EMBOLISM; CANCER LOCALIZATION; CANCER SIZE; CANCER SURGERY; COLORECTAL CANCER; COLORECTAL TUMOR; COMORBIDITY; CYTOREDUCTIVE SURGERY; HORMONE SYNTHESIS; HUMAN; LIVER METASTASIS; LIVER SIZE; LIVER SURGERY; MICROWAVE THERAPY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RADIOFREQUENCY ABLATION; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELECTIVE INTERNAL RADIATION THERAPY; STEREOTACTIC BODY RADIATION THERAPY;

EID: 84874605904     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0023     Document Type: Article

References (51)

1. Sacks A, Peller PJ, Surasi DS, et al. Value of PET/CT in the management of liver metastases, part 1. AJR Am J Roentgenol 2011;197:W256-259.
2. Reddy SK, Clary BM. Neuroendocrine liver metastases. Surg Clin North Am 2010;90:853-861.
3. Groeschl RT, Nachmany I, Steel JL, et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg 2012;214:769-777.
4. De Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009;250:440-448.
5. Ciliberto D, Prati U, Roveda L, et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep 2012;27:1849-1856.
6. Abdalla EK. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 2010;102:960-967.
7. Wicherts DA, De Haas RJ, Andreani P, et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 2010;97:240-250.
8. Poultsides GA, Schulick RD, Pawlik TM. Hepatic resection for colorectal metastases: the impact of surgical margin status on outcome. HPB (Oxford) 2010;12:43-49.
9. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318.
10. Nathan H, de Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg 2010;210:755-764.
11. Tsai S, Marques HP, De Jong MC, et al. Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) 2010;12:262-269.
12. De Jong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009;13:2141-2151.
13. Mayo SC, De Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010;17:3129-3136.
14. Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012;2012:819193.
15. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery 2008;144:645-651; discussion 651-653.
16. Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J 2010;16:111-117.
17. Machi J, Oishi AJ, Sumida K, et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006;12:318-326.
18. Van Duijnhoven FH, Jansen MC, Junggeburt JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol 2006;13:651-658.
19. Wu YZ, Li B, Wang T, et al. Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol 2011;17:4143-4148.
20. Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242:158-171.
21. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29-37.
22. Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol 2009;38:135-143.
23. Martin RC, Scoggins CR, Mcmasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2009;17:171-178.
24. Jones C, Badger SA, Ellis G. The role of microwave ablation in the management of hepatic colorectal metastases. Surgeon 2011;9:33-37.
25. Lloyd DM, Lau KN, Welsh F, et al. International multicentre prospective study on microwave ablation of liver tumours: preliminary results. HPB (Oxford) 2011;13:579-585.
26. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012;32:1387-1395.
27. Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Semin Oncol 2010;37:118-126.
28. Mayo SC, De Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011;18:3657-3665.
29. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
30. Kingham TP, D'angelica M, Kemeny NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol 2010;102:988-995.
31. Bouchahda M, Levi F, Adam R, Rougier P. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur J Cancer 2011;47:2681-2690.
32. Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009:CD007045.
33. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78-85.
34. Kalinowski M, Dressler M, Konig A, et al. Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 2009;79:137-142.
35. Kennedy AS, Dezarn WA, Mcneillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90y-microspheres: early results in 148 patients. Am J Clin Oncol 2008;31:271-279.
36. Shaheen M, Hassanain M, Aljiffry M, et al. Predictors of response to radio-embolization (Thera Sphere®) treatment of neuroendocrine liver metastasis. HPB (Oxford) 2012;14:60-66.
37. Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 2011;117:4060-4069.
38. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572-1578.
39. Bhardwaj N, Strickland AD, Ahmad F, et al. Microwave ablation for unresectable hepatic tumours: clinical results using a novel microwave probe and generator. Eur J Surg Oncol;36:264-268.
40. Ogata Y, Uchida S, Hisaka T, et al. Intraoperative thermal ablation therapy for small colorectal metastases to the liver. Hepatogastroenterology 2008;55:550-556.
41. Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation-complications among cohort of 1136 patients. Radiology 2009;251:933-940.
42. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-825; discussion 825-827.
43. Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 2005;90:36-42.
44. Veltri A, Sacchetto P, Tosetti I, et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol 2008;31:948-956.
45. Reuter NP, Woodall CE, Scoggins CR, et al. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg 2009;13:486-491.
46. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008;247:1029-1035.
47. Hendlisz A, Van Den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010;28:3687-3694.
48. Nace GW, Steel JL, Amesur N, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol 2011;2011:571261.
49. Martin LK, Cucci A, Wei L, et al. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer 2012;11:195-199.
50. Kucuk ON, Soydal C, Lacin S, et al. Selective intraarterial radionuclide therapy with yttrium-90 (y-90) microspheres for unresectable primary and metastatic liver tumors. World J Surg Oncol 2011;9:86.
51. Erratum in World J Surg Oncol 2011;9:120.